A PHASE 3B, OPEN-LABEL, SINGLE-ARM, ROLLOVER STUDY TO EVALUATE LONG-TERM SAFETY IN SUBJECTS WHO HAVE PARTICIPATED IN OTHER LUSPATERCEPT(ACE-536) CLINICAL TRIALS

Registry ID

ACE-536-LTFU-001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BRISTOL-MYERS SQUIBB CANADA

Start date

2020-03-27

Last update

2019-02-25

Conditions

• ANEMIA
• BETA-THALASSEMIA

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALN-CFB, AN INVESTIGATIONAL SIRNA THERAPEUTIC AGAINST COMPLEMENT FACTOR B, IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND PERSISTENT ANEMIA ON APPROVED C5-INHIBITOR THERAPY
• A PHASE 2, RANDOMIZED, OPEN-LABEL, STUDY OF MOMELOTINIB IN PARTICIPANTS WITH ANEMIA DUE TO LOW-RISK MYELODYSPLASTIC SYNDROME
• A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-R) VERY LOW, LOW, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS) IN ERYTHROPOIESISSTIMULATING AGENT (ESA)-NAIVE PARTICIPANTS WHO ARE NON-TRANSFUSION DEPENDENT (NTD): THE ¿ELEMENT-MDS¿ TRIAL
• FEASIBILITY AND EFFICACY OF INTRAVENOUS FERRIC DERISOMALTOSE TO CORRECT PRE-OPERATIVE IRON-DEFICIENCY ANEMIA IN PATIENTS UNDERGOING GYNECOLOGIC ONCOLOGY SURGERY: A PILOT RANDOMIZED DOUBLE BLINDED PARALLEL GROUP PLACEBO-CONTROLLED STUDY
• A LONG-TERM FOLLOW-UP STUDY OF SUBJECTS WITH BETA-THALASSEMIA OR SICKLE CELL DISEASE TREATED WITH AUTOLOGOUS CRISPR-CAS9 MODIFIED HEMATOPOIETIC STEM CELLS (CTX001)
• A RANDOMIZED DOUBLE-BLINDED PHASE II STUDY TO DETERMINE TREATMENT PROTOCOL FOR HEMOGLOBIN OPTIMIZATION TO PREVENT TRANSFUSION AND ADVERSE EVENTS IN PERIOPERATIVE PATIENTS WITH IRON RESTRICTED ANEMIA ¿ HOPE-HB STUDY

View on source registry